Journal
TRENDS IN MOLECULAR MEDICINE
Volume 12, Issue 10, Pages 480-487Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2006.08.006
Keywords
-
Funding
- NCI NIH HHS [CA099506, CA103999] Funding Source: Medline
- NIAMS NIH HHS [AR050200, AR050966] Funding Source: Medline
Ask authors/readers for more resources
Genetic mutations that lead to an accumulation of farnesyl-prelamin A cause progeroid syndromes, including Hutchinson-Gilford progeria syndrome. It seemed possible that the farnesylated form of prelamin A might be toxic to mammalian cells, accounting for all the disease phenotypes that are characteristic of progeria. This concept led to the hypothesis that protein farnesyltransferase inhibitors (FTIs) might ameliorate the disease phenotypes of progeria in mouse models. Thus far, two different mouse models of progeria have been examined. In both models, FTIs improved progeria-like disease phenotypes. Here, prelamin A post-translational processing is discussed and several mutations underlying human progeroid syndromes are described. In addition, recent data showing that FTIs ameliorate disease phenotypes in a pair of mouse models of progeria are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available